Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 07, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to follow along as we highlight milestone moments for our portfolio companies.
Funding News
01/
Zhipu AI Closes New Strategic Funding Round of Over RMB 1 Billion
Recently, Qiming Venture Partners portfolio company Zhipu AI completed a new strategic funding round of over RMB 1 billion. The proceeds will drive technological innovation and ecosystem development around its domestic GLM foundation models, leverage regional AI industry layout advantages, and support digital industry transformation powered by artificial intelligence.
As China's earliest open-source large model AI company, Zhipu AI has been committed to making AI accessible to all. 2025 will also be Zhipu AI's "Year of Open Source." The company plans to release new large models — including foundation models, reasoning models, multimodal models, and Agents — and open-source them.
02/
Pulnovo Medical Raises Nearly USD 100 Million in Series C Round Co-Led by Qiming Venture Partners
Recently, innovative medical device company Pulnovo Medical announced the completion of a nearly USD 100 million Series C round, co-led by Qiming Venture Partners. The funding will primarily advance Pulnovo Medical's global clinical programs, overseas operations, and strategic development plans.
Notably, this round was oversubscribed twice, making it the largest market-driven financing in the Asia-Pacific innovative medical device sector in recent years — a clear signal that top-tier investment institutions fully trust Pulnovo Medical's internationalization strategy and professional capabilities.
Founded in 2013, Pulnovo Medical focuses on delivering breakthrough therapies for pulmonary hypertension and heart failure, enhancing patients' resilience and quality of life. As a pioneer of China-origin devices recognized in international guidelines, the company leverages its deep clinical resources to pursue cutting-edge scientific exploration and globally minded commercialization, striving to create superior solutions at every stage of heart failure to delay and improve disease progression, and reshape the treatment landscape for heart failure through technological innovation.
William Hu, Managing Partner at Qiming Venture Partners, said: "Pulnovo Medical's innovative breakthroughs in pulmonary hypertension and heart failure interventional therapy are remarkable. Its self-developed PADN technology has not only begun commercial sales in mainland China, Hong Kong, and Macau, but also embarked on internationalization in 2024, with global multi-center clinical trials underway in Portugal, Serbia, Georgia, and Southeast Asia. Following its successful FDA Breakthrough Device Designation, the launch of global clinical programs further demonstrates the technology's world-leading position and clinical value. As a long-term investor in healthcare, Qiming Venture Partners remains committed to supporting innovative companies with a global vision. We are highly optimistic about Pulnovo Medical's tremendous potential in pulmonary hypertension and heart failure, and will fully support its international expansion and commercialization to help bring China-origin technology to the world and offer new hope to patients globally."
Major Partnerships
01/
WeRide Signs Strategic Partnership with Singapore's CTM
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology firm WeRide (NASDAQ: WRD) formally signed a strategic partnership with Singapore's renowned environmental sanitation company Chye Thiam Maintenance (CTM). The two parties will deepen collaboration in L4 autonomous driving sanitation vehicles (Robosweeper), jointly driving scaled commercial deployment of the product in Singapore and international markets.
Tony Han, Founder and CEO of WeRide, said: "Singapore is a critical anchor for WeRide's global strategy and a benchmark market for autonomous driving technology applications. We look forward to exploring innovative pathways for autonomous driving in urban services together with CTM — from diverse product exports to joint technology ecosystem building — providing scalable, replicable 'WeRide solutions' for smart city development worldwide."
02/
Roborock Partners with Shanghai Astronomy Museum to Launch Hardcore New Products
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) held its 2025 product launch themed "Reimagining Cleaning" at the Shanghai Astronomy Museum, hoping to infuse the spirit of exploration into home technology through the frontier concept of space exploration.
Qian Qijie, President of Roborock's Cleaning Products BU, announced at the event that Roborock has become an authorized partner of the Shanghai Astronomy Museum. The company hopes to further simplify household cleaning and reimagine what's possible — bridging aerospace technology to home technology — so life feels more premium.
During the launch, Roborock unveiled multiple cleaning products, including the G30 Space Explorer Edition with the world's first five-axis biomimetic folding robotic arm, the G30 featuring debut tri-line structured light obstacle avoidance technology, and the ultra-slim G30U at 7.98cm with powerful suction. Also introduced was the A30 Pro Steam, Roborock's first steam-and-hot-water dual-mode floor washer.
03/
UBTECH Subsidiary UQI Signs Strategic Partnership with Singapore's M8M
Recently, UQI, a subsidiary of Qiming Venture Partners portfolio company UBTECH (09880.HK), signed a strategic partnership agreement with Singapore's M8M Pte Ltd (M8M), establishing a long-term, comprehensive strategic relationship. Centered on the theme of "innovative unmanned logistics applications at airports," both parties will leverage their respective strengths to accelerate the deployment of unmanned logistics solutions in the airport sector.
As fellow advocates and practitioners of unmanned logistics, UQI and M8M each bring distinct strengths — UQI in logistics robotics products and technology, M8M in rich airport transport scenarios. Under the strategic partnership, both parties will leverage their respective advantages for mutual complementarity and win-win outcomes. Through product integration and system interconnection, they will develop and deploy an industry-leading unmanned logistics solution for airports, achieving unmanned logistics and full information control across indoor and outdoor airport scenarios. This will address long-standing pain points in airport transport: high labor and management costs, harsh operating environments, and safety concerns, while significantly improving logistics efficiency, optimizing transport and management costs, and enhancing service quality — contributing to smarter, more efficient, connected, and low-carbon airport logistics.
04/
Pangda Group Partners with Shangyue
To Launch Enterprise Supplier Management and Procurement SaaS Platform
Recently, Pangda Group partnered with Qiming Venture Partners portfolio company Shangyue to officially launch its enterprise supplier management and procurement SaaS platform project.
In this collaboration, Shangyue will provide Pangda Group with advanced procurement digitalization solutions based on its intelligent procurement platform, the Sunyur Air SaaS application, assisting Pangda in achieving comprehensive digital upgrading of its procurement processes. The partnership will connect upstream and downstream supply chains, enabling full optimization of product procurement, data analytics, and other processes — ultimately delivering transparent workflows, controllable costs, and improved efficiency for the Group.
05/
Insilico Medicine Announces Preclinical Milestone
in Collaboration with Therasid Bioscience
Recently, Qiming Venture Partners portfolio company Insilico Medicine announced that it had reached a significant preclinical milestone in its collaboration with Therasid Bioscience.
The collaboration between Insilico Medicine and Therasid Bioscience centers on AI-driven development of MASH therapies. In the partnership, Insilico Medicine optimized a series of candidate compounds targeting particularly challenging targets provided by Therasid Bioscience, with a focus on improving ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. Leveraging its AI-powered generative chemistry platform Chemistry42, the R&D team successfully identified candidate compounds with the desired physicochemical properties after synthesizing and testing approximately 40 molecules in just four months. These molecules will now be advanced by Therasid Bioscience through further development, including in vitro and in vivo preclinical validation.
06/
Goodwill Healthcare and GemPharmatech Enter Comprehensive Strategic Partnership
Recently, Qiming Venture Partners portfolio company Goodwill Healthcare (688246.SH) formally signed a comprehensive strategic cooperation agreement with GemPharmatech.
Both parties will fully leverage their respective strengths in healthcare informatization and innovative model development, conducting deep collaborative cooperation across three domains: precision oncology, clinical trial design optimization, and real-world evidence studies. Together they will build a closed-loop system for innovative drug R&D, driving innovation and development in the biopharmaceutical industry.
07/
Shukun Technology Partners with Shenzhen People's Hospital and Huawei
To Build Comprehensive Digital Intelligent Hospital Solution
Recently, Shenzhen People's Hospital, Qiming Venture Partners portfolio company Shukun Technology, and Huawei reached an in-depth tripartite cooperation. The parties achieved on-premises deployment of the DeepSeek-R1 model and Shukun's "Shukun Kun" multimodal medical health large model, and are jointly building a comprehensive digital intelligent hospital solution based on medical specialty large models. This will inject strong momentum into the hospital's medical and research capabilities, opening a new chapter in hospital-wide medical intelligence.
The platform, powered by DeepSeek and the "Shukun Kun" multimodal medical health large model, will provide comprehensive research support for Shenzhen People's Hospital. It will not only enable rational evaluation and recommendations for research design, but also leverage the model's understanding of medical data to rapidly construct multimodal databases required for studies.
R&D Progress
01/
Gan & Lee Pharmaceuticals' Bofanglutide (GZR18) Injection Completes First Patient Dosing in Phase 3 OPTIMUM-1 Clinical Study
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) biweekly formulation, bofanglutide (development code: GZR18) injection, completed first patient dosing in a Phase 3 clinical study (OPTIMUM-1) in Chinese type 2 diabetes (T2DM) subjects. This marks the second large-scale Phase 3 clinical study for the T2DM indication for bofanglutide injection.
Gan & Lee Pharmaceuticals' bofanglutide injection is a biweekly GLP-1RA targeting weight management in adults with type 2 diabetes and obesity/overweight individuals. As a potential world's first biweekly GLP-1 formulation, early clinical data showed comparable or even superior weight loss efficacy compared to currently marketed products, with safety and tolerability profiles consistent with GLP-1 drug characteristics, effectively reducing blood glucose levels and body weight. Bofanglutide injection has now advanced to Phase 3 clinical development globally.
02/
Insilico Medicine Discovers Innovative Oral Covalent CDK12/13 Dual-Target Inhibitor
Recently, Qiming Venture Partners portfolio company Insilico Medicine announced the discovery of a series of innovative oral covalent CDK12/13 dual-target inhibitors, offering potential new treatment options for refractory and drug-resistant cancers. The findings were published in the leading medicinal chemistry journal Journal of Medicinal Chemistry (impact factor: 7.2).
The article describes the development of compound 12b, a candidate drug targeting CDK12/13 with favorable efficacy, selectivity, and safety profiles. Its development benefited from Insilico Medicine's proprietary generative AI platforms PandaOmics and Chemistry42.
03/
CanSino Biologics' DTcP-Hib-MCV4 Combined Vaccine Receives Clinical Trial Approval
Recently, Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK) received a Clinical Trial Approval Notification for its adsorbed acellular pertussis (component) – diphtheria – tetanus – Haemophilus influenzae type b (conjugate) – group ACYW135 meningococcal (conjugate) combined vaccine (hereinafter referred to as the "DTcP-Hib-MCV4 combined vaccine") from the National Medical Products Administration.
This clinical approval for the combined vaccine represents not just a breakthrough for a single product, but a significant milestone in CanSino Biologics' strategic positioning in innovative multivalent and combination vaccines.
Multivalent and combination vaccines address logistical challenges and costs through fewer injections, reducing pain for children, saving parents time, improving vaccination efficiency for health authorities, and lowering the risk of adverse reactions. As a result, developing and promoting combination vaccines that simultaneously prevent multiple diseases has become a trend in new vaccine R&D, with strong prospects for clinical development.
04/
Ticarum Bio Announces Phase 2 Interim Data for LP-003 in Chronic Spontaneous Urticaria
Recently, Qiming Venture Partners portfolio company and Chinese innovative biopharmaceutical firm Ticarum Bio presented interim Phase 2 clinical data for its self-developed next-generation anti-IgE antibody LP-003 in chronic spontaneous urticaria (CSU) at the 2025 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2025). The results showed that LP-003 outperformed the existing anti-IgE therapy omalizumab on key efficacy endpoints while demonstrating long-acting advantages, positioning it as a potentially disruptive therapy in the global anti-IgE treatment landscape.
Beyond beating Roche's first-generation anti-IgE antibody omalizumab in a head-to-head comparison, LP-003's absolute UAS7 reduction was comparable to that of Barzolvolimab, the anti-C-KIT monoclonal antibody from United States-based Celldex, with no adverse reactions similar to those seen with Barzolvolimab. With its faster clinical improvement, more durable effects, and better safety profile, LP-003 is well-positioned to capture a leading share of the global allergy therapeutics market, which exceeds $10 billion.
05/
Ze'an Biopharmaceutical's First-in-Class Myeloid Engager Immunotherapy LTZ-301 Receives IND Approval
Qiming Venture Partners portfolio company Ze'an Biopharmaceutical recently announced that the FDA has approved the Investigational New Drug (IND) application for its first product, LTZ-301.
LTZ-301 is a first-in-class myeloid engager immunotherapy based on Ze'an Biopharmaceutical's proprietary Myeloid Engager Platform. It is the first candidate in the company's pipeline to enter clinical trials. This IND approval will initiate initial proof-of-concept (POC) for this innovative therapy and bring new breakthroughs to the immunotherapy field. Ze'an Biopharmaceutical plans to launch an open-label, multicenter Phase 1 clinical study in Q2 2025 to evaluate LTZ-301's therapeutic potential in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Product Launches
01/
Xiaomi Unveils Xiaomi 15 Ultra and Multiple New Products
Recently, Qiming Venture Partners portfolio company Xiaomi (01810.HK) launched a suite of new products including the Xiaomi 15 Ultra, Xiaomi SU7 Ultra, Xiaomi Buds 5 Pro, REDMI Book Pro 2025 series, Xiaomi Smart Speaker Pro, Mijia Central AC Pro, Mijia Smart Dehumidifier Pro, Mijia Refrigerator Pro Dual System, and Mijia Washer-Dryer Set Pro.
Since the Xiaomi 12S Ultra first partnered with Leica, Xiaomi has continued to lead the optical revolution and aesthetic evolution in mobile imaging. The Xiaomi 15 Ultra not only solves mobile imaging's persistent challenge of night photography, but also integrates Xiaomi Star Communication, the Leica Ultra-Pure Optical System, and Xiaomi's proprietary battery technology, redefining the convergence of mobile imaging and flagship technology.
As a leader in mobile optics, Xiaomi and Leica have collaborated to create the most extreme miniaturized optics possible and achieve the purest night scene image quality. Together they developed the Leica Ultra-Pure Optical System, applying full-chain extreme optical design to every step of light's journey from the first lens element to the sensor for the first time, using extensive new materials, technologies, and manufacturing processes to achieve end-to-end optical fidelity.
The Xiaomi 15 Ultra features Xiaomi's most advanced battery to date, achieving 10% ultra-high silicon content that boosts capacity by 700mAh over the previous generation to 6,000mAh total. In Xiaomi's lab testing, it delivered up to 1.46 days of extended battery life.
The Xiaomi SU7 Ultra incorporates numerous era-leading intelligent technologies to comprehensively meet users' smart mobility needs, delivering an advanced intelligent living experience that connects the "human-car-home" ecosystem. The SU7 Ultra comes standard with Xiaomi HAD end-to-end full-scenario autonomous driving, enabling point-to-point intelligent driving. Meanwhile, Xiaomi HyperOS Smart Cockpit provides drivers with integrated navigation, entertainment, and vehicle control.
02/
Yunji Technology Launches UP Cleaning Robot
Recently, Qiming Venture Partners portfolio company Yunji Technology launched the UP cleaning robot.
Designed specifically for hotel carpets, the product delivers 20,000Pa of suction power to instantly clean common debris from public area carpets. Its 3,600 RPM brush rotation speed leads comparable industry products by 3-6x, enabling deep cleaning. The robot dynamically adjusts brush height to intelligently adapt to carpet thickness. H12-grade HEPA filtration prevents secondary air pollution during cleaning. It performs deep cleaning at low noise levels and flexibly responds to cleaning needs in meeting rooms, corridors, and banquet halls around the clock.
Technology & Capabilities
01/
WeRide Launches Europe's First L4-Level Fully Driverless Robobus Commercial Operation
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology company WeRide (NASDAQ: WRD) partnered with Renault Group, French autonomous mobility operator beti, and insurance group Macif to launch L4-level autonomous mobility services in France's Drôme department — WeRide's first fully driverless Robobus commercial deployment on European public roads.
The project marks an unprecedented collaboration among four industry leaders, united by a shared vision: that accessible, shared autonomous mobility should cover both urban and suburban areas, drive the green transportation transition, and provide residents with more convenient solutions for commuting to work, accessing healthcare, education, and leisure.
The shuttle service deployed at the Rovaltain Business Park breaks new ground on several fronts. It represents WeRide's first fully driverless commercial deployment of L4 autonomous driving technology on European public roads, adding a new chapter to the company's global expansion. It is also Europe's first L4 autonomous mobility network connecting a railway station to a surrounding business park, developed jointly by WeRide, Renault Group, and beti. The WeRide Robobus is designed to comply with local traffic regulations, operating at compliant speeds (up to 40 km/h) with dynamic obstacle avoidance capabilities.
02/
Superhexa Debuts Jiehuan AI Audio Glasses at Shanghai International Optics Fair
Recently, Qiming Venture Partners portfolio company Superhexa unveiled its proprietary brand Jiehuan's AI audio glasses at the 23rd China (Shanghai) International Optics Fair (SIOF).
Yongfeng Xia, founder and CEO of Superhexa, noted that the prerequisite for making good smart glasses is first building a quality pair of glasses — the core lies in satisfying the fundamental product attributes of "good-looking and comfortable," with digital features coming second. As large AI models become more widely deployed, smart glasses will evolve from single-purpose assistive tools into integrated terminal products capable of real-time interaction, information processing, and personalized services. The value of smart glasses lies not only in technological innovation but in how genuinely they integrate into users' daily lives — empowering the eyewear industry with technology while creating new opportunities and growth for the sector as a whole.
03/
PETKIT Upgrades AI-Powered Image Capture Algorithm for Smart Litter Boxes
Recently, Qiming Venture Partners portfolio company PETKIT has comprehensively upgraded the image capture algorithm for its smart visual litter box series, with AI at the core.
The product has evolved from single-frame snapshot mode to multi-dimensional capture, enabling it to photograph pet urine clumps and feces from multiple angles and generate a series of photos from different perspectives. This effectively prevents the information gaps caused by a single viewpoint, allowing users to gain a more comprehensive and in-depth understanding of their pet's health.
04/
Yingying Medical Becomes Among First Private Medical Institutions in Shanghai to Complete PFA Procedures
Recently, the cardiac care center at Qiming Venture Partners portfolio company Yingying Medical successfully performed minimally invasive surgeries on two atrial fibrillation patients using globally leading pulsed field ablation (PFA) technology. This marks Yingying Medical's entry into a new phase of precision and efficiency in arrhythmia treatment, bringing renewed hope for recovery to more AFib patients. Yingying Medical has also become one of the first private medical institutions in Shanghai to complete PFA procedures.
Leveraging Yingying Medical's multidisciplinary resources, the cardiac care center adopts a "general practice + specialty" model with international standards and clinical protocols. Committed to a "patient-centered" approach, it provides comprehensive patient assessments and one-stop cardiac health management encompassing disease prevention, diagnosis, pharmaceutical and surgical treatment, and rehabilitation guidance.
05/
Berry Genomics Supports Launch of 100,000-Couple Carrier Screening Multicenter Prospective Clinical Cohort Study
Recently, the closing meeting of the national key R&D program "Reproductive Health and Maternal and Child Health Protection" key special project "CSRMed Multicenter Clinical Research" — and the launch meeting of the "100,000-Couple Carrier Screening Multicenter Prospective Clinical Cohort Study" — was successfully held in Shanghai. The event was hosted by Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine and co-organized by Qiming Venture Partners portfolio company Berry Genomics (000710.SZ).
The 100,000-couple carrier screening multicenter prospective clinical cohort study aims to map the carrier frequency of recessive monogenic disorders in the Chinese population through broad-based screening. Tailored to the genetic characteristics of Chinese populations, it will optimize carrier screening protocols for recessive monogenic disorders to improve screening efficiency and accuracy — enabling early screening and effective intervention for recessive monogenic diseases among people of childbearing age, and effectively reducing birth defects.
As a project collaborator and technology provider, Berry Genomics will fully support the initiative with its professional expertise and innovative R&D capabilities, providing scientific support for upgrading China's three-tier birth defect prevention system and contributing technological strength to the Healthy China initiative.
06/
Qianmai Medical's Beijing Clinical Laboratory Passes CNAS ISO15189 Medical Laboratory Accreditation On-Site Review
Recently, Beijing Qianmai Medical Laboratory Co., Ltd. ("Beijing Qianmai"), a subsidiary of Qiming Venture Partners portfolio company Qianmai Medical, announced that it has passed the on-site review for ISO15189 medical laboratory accreditation by the China National Accreditation Service for Conformity Assessment (CNAS).
Ms. Li Li, General Manager of Beijing Qianmai, stated that this review represents not only a comprehensive assessment of the company's quality system and operations but also a catalyst for sustained development. Beijing Qianmai will further optimize its quality management system and operational efficiency based on the expert panel's recommendations, while also incorporating employee feedback into the company's development planning to create a better working environment and growth opportunities for its staff.
07/
Bondent Subsidiary Brand Introduces New OM Technology
Recently, a subsidiary brand of Qiming Venture Partners portfolio company Bondent — Bondent CBCT — launched its new OM technology (Oneshot-Multimodal imaging technology). With "low radiation, artifact-free" imaging at its core, it ushers in a new era for dental imaging.
OM technology enables simultaneous reconstruction of CBCT and panoramic images from a single scan (with large-field data also automatically generating cephalometric images — a "three-in-one" imaging solution). This not only significantly reduces radiation dosage but also completely eliminates metal artifacts. Whether for teeth, jawbones, or implant anatomical relationships, OM technology delivers clear visualization, providing reliable support for precise clinical diagnosis and treatment planning.
08/
ZhenGe Biologics Presents at 6th ADC Drug Development Conference
At the 6th ADC Drug Development Conference, Qiming Venture Partners portfolio company ZhenGe Biologics showcased its large-molecule CDMO services, ADC CDMO solutions, custom media development and manufacturing services, and analytical testing services.
ZhenGe Biologics provides comprehensive CDMO services from preclinical development through commercial manufacturing, accelerating and advancing the R&D and industrialization of large-molecule biologics for pharmaceutical companies and research institutions worldwide.
09/
Beijing Zuoyi Technology's Medical Transcription Robot Supports Sichuan Provincial People's Hospital in Building Smart Healthcare Benchmark
Recently, Sichuan Provincial People's Hospital deployed Beijing Zuoyi Technology's medical transcription robot and other solutions in clinical settings, becoming the first Class III hospital in the province to achieve full-scenario intelligent healthcare deployment.
Beijing Zuoyi Technology's transcription robot uses a medical vertical large model as its intelligent foundation. It can analyze doctor-patient conversations in real time and provide intelligent prompts to assist with consultations. It also recommends relevant medical knowledge to physicians based on dialogue content, improving consultation efficiency through premium literature recommendations, care plan suggestions, and medication knowledge alerts. Powered by medical large language model-based medical record generation technology, the device produces standardized medical records upon consultation completion for physician confirmation, with seamless integration into the outpatient electronic medical record system. Patients can scan a QR code to establish a connection, receive medical instructions, and be guided from offline to online hospital services — creating a closed loop between online and offline care. After their visit, patients can conveniently access medical orders and educational content, and schedule online follow-up consultations as needed. The physician management backend allows browsing, searching, and reviewing consultation content and generated professional medical records.
10/
Ruikang Hospital Affiliated with Guangxi University of Chinese Medicine Team Completes High-Difficulty Surgery Using Tingsn Technology Intracardiac Ultrasound Product
Recently, Professor Fan Yue's thoracic and cardiovascular surgery team at Ruikang Hospital Affiliated with Guangxi University of Chinese Medicine successfully performed a high-difficulty left pulmonary artery stent implantation on a patient with post-surgical pulmonary artery stenosis following complex congenital heart surgery. The procedure was conducted under the guidance of Tingsn Technology's intracardiac echocardiography (ICE) product, opening a life channel for a patient post-tetralogy of Fallot (TOF) repair.
TINGSN Sonic Eyes 10 is Tingsn Technology's independently developed first domestic intracardiac ultrasound diagnostic catheter. The catheter has a diameter of 10Fr (3.3mm), an effective length of 95cm, and a segmented design allowing 160° bending in four directions — anterior, posterior, left, and right. When connected with the TINGSN FINDERS 1 portable color ultrasound diagnostic system, the Sonic Eyes 10 disposable intracardiac ultrasound diagnostic catheter enables surgeons to observe cardiac structures and adjacent tissues from inside the heart at 360° and monitor intraoperative complications in real time. The TINGSN Sonic Eyes 10 allows surgeons to perform procedures with zero fluoroscopy, significantly reducing X-ray exposure time for both surgeons and patients and lowering associated radiation risks. Additionally, through simple operation, the device obtains more accurate ultrasound images of cardiac chambers and accessory structures, reducing the risk of cardiac perforation or cardiac tamponade and substantially improving surgical safety.
11/
Shukun Technology's Four AI Product Suite Receives EU Medical Device Regulation Certification
Recently, Shukun Technology, a Qiming Venture Partners portfolio company and global leader in medical AI, announced that its independently developed four-AI-product suite has officially received European Union Medical Device Regulation (MDR) certification. To date, Shukun Technology has accumulated 8 MDR certifications covering the three core organs — heart, brain, and chest — making it the only innovative enterprise globally to achieve full-scenario deployment in imaging AI for vital organs.
The newly approved suite significantly improves diagnostic accuracy and enhances clinical decision-making efficiency. As the only company with MDR certifications across all three critical domains of heart, brain, and chest, Shukun Technology has built intelligent solutions covering the full process from prevention, screening, and diagnosis to treatment through continuous medical-engineering innovation.
Corporate Honors
Infinigence AI Wins Best Paper Award at FPGA 2025, Top Conference in Reconfigurable Computing
Recently, FlightVGM, a video generation model inference IP work led by Qiming Venture Partners portfolio company Infinigence AI and others, received the Best Paper Award at FPGA 2025, the top international conference in reconfigurable computing. This marks the first time the FPGA conference has granted this award to research work entirely led by a mainland China-based scientific team, and also the first time a team from an Asia-Pacific country has received this honor.
This research work achieved, for the first time, efficient inference of video generation models (VGMs) on FPGA. It is the latest installment in the team's series following last year's FPGA acceleration of large language models, FlightLLM (FPGA 2024). Compared with the NVIDIA 3090 GPU, FlightVGM achieved 1.30× performance improvement and 4.49× energy efficiency improvement on the AMD V80 FPGA — despite a peak compute gap exceeding 21×.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 06, 2025 Qiming Stars | Pulnovo Medical Raises Nearly $100 Million in Series C Funding, Qiming Venture Partners Co-Leads | Bilingual
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises. Among these, more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), New Horizon Health (06606.HK), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, and Biren Technology.